Protecting Respiration During Conscious Sedation Using Inspired
Carbon Dioxide: A Simulation Study
D ARRYL K. Z ITTING
Department of Bioengineering, University of Utah, Salt Lake City, UT

events.12,22,7,10 The American Society for Gastrointestinal
Endoscopy reports that only 76% of its endoscopists are
certified in Basic Life Support and only 30.2% of them
are certified in Advanced Cardiopulmonary Life Support
with the ability to perform intubation.12 These figures
indicate the need to insure safety from respiratory
depression for patients undergoing conscious sedation.
Arterial CO2 provides the fast feedback control of
respiration to maintain gas exchange equal to metabolic
production.
When a respiratory depressant is
administered, CO2 builds up and the body responds by
increasing respiratory drive.3,5 Fast-onset anesthetics
cause more severe respiratory depression because the
body has less time to build up CO2 to counter the
respiratory depression of the drug.2,5,14 Thus, these drugs,
while good for patient turn around, pose a greater risk of
respiratory depression and apnea.2,5,14 Fast acting drugs,
large patient variability and a small therapeutic window
between sufficient sedation and apnea make it difficult for
sedationists to titrate to the needed level of sedation
without overshooting into apnea.2,5,14
There is a need to widen the therapeutic window for
conscious sedation by increasing the range of safe drug
concentration between sufficient sedation and over
sedation. I propose to accomplish this by elevating the
patients arterial CO2 by administering a low concentration
of inspired CO2 during drug administration effectively
increasing respiratory drive to counter the depressant
effect of the drug. This article will describe the
application of a numerical model as a proof of concept for
the respiration protection system.

Abstract−Conscious sedation procedures require sedation and
analgesia sufficient for the particular procedure but not so deep
as to cause apnea. Fast acting sedatives such as Propofol are
increasingly used in these procedures although they cause more
severe respiratory depression than more traditional sedatives
such as Midazolam. A method was devised to maintain
respiration during conscious sedation by administering inspired
CO2 as a respiratory stimulant to offset the reduced respiratory
drive caused by Propofol. A computer model was implemented
which predicts respiratory depression caused by Propofol
administration. Simulations of common dosing regimens were
performed with and without inspired CO2. For all dosing
regimens, adding inspired CO2 prevented the respiration from
falling as much as the control and respiration returned to
baseline within 4 to 6 minutes. Administering inspired CO2
during conscious sedation seems to be an effective way to
prevent respiratory depression according to the best available
numerical model.
Keywords−Rebreathing, Conscious sedation, Procedural
sedation, Carbon Dioxide, Computer modeling, Propofol.

INTRODUCTION
Conscious sedation is light sedation where the patient
maintains spontaneous breathing and is used during such
common procedures include endoscopy, cardioversion,
defibrillator implantation, tonsillectomy and dental
surgery.12,22 Surgical procedures requiring conscious
sedation are very common, accounting for an estimated
200 million surgical procedures per year in the U.S.11
The economics of procedures requiring conscious
sedation make it impossible to have an anesthesiologist
attending to the drug administration. In many cases, a
nurse or even the physician performing the procedure
must act as the sedationist. Over-sedation is a common
leading factor causing cardiopulmonary problems during
and after the procedure.7 Respiratory problems like apnea
and respiratory depression account for up to 70% of all
adverse events occurring during procedures requiring
conscious sedation.10
While respiratory complications account for most
adverse events during conscious sedation, many of the
sedationists are not well trained to respond to adverse

MATERIALS AND METHODS
Respiratory Simulator
Bouillon et al developed and validated a respiratory
model which describes the non-steady state changes in
alveolar ventilation caused by Propofol.5 Propofol is a
fast acting sedative-hypnotic with a half life of 2-4
minutes and a substantial respiratory depressant effect.21,6
The Bouillon model takes effect site Propofol
concentration as an input and calculates respiratory
depression based on a sigmoid Emax model often used to
describe Propofol effect.5 Bouillon derived and validated
the model parameters with a volunteer study. See the
appendix for a description of the model derivation as well
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as model parameters. Bouillon makes a simplification in
his derivation by assuming that inspired CO2 will be close
to zero for spontaneously breathing patients. I modified
Bouillon's model to account for inspired CO2 by
modifying the term representing the gradient across the
blood pulmonary barrier to be the difference between
arterial and inspired partial pressures of CO2, giving the
following expression:
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site concentration. The controller was made to limit
inspired carbon dioxide below 10%.
d


PiCO2 (t ) = K p  error(t ) + Ki ∫ error(t )dt + Kd error(t ) 
dt
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where,

error(t ) = Valvsp − Valv(t)

Valvsp = Desired Alveolar Ventialtion
(1)
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where,

PaCO 2 (0 ) = Baseline arterial pCO 2 (mmHg).
PaCO 2 (t ) = Arterial pCO 2 at time ' t' (mmHg).
V&alv ( 0) = Baseline alveolar ventilatio n (L/min).
V& (t ) = Alveolar ventilatio n at time ' t' (L/min).
alv

V d CO 2 = Apparent volume of distributi on (L).
Ce (t ) = Effect site propofol conc. (ug/ml).
C 50 = Effect site propofol conc. correspond ing
to 50% effect (µµg/ml)
PecCO 2 = Effect site pCO 2 (mmHg).

γ = Hill coefficien t.
F = Gain factor for non − linear CO 2
response curve.
PiCO 2 = partial pressure of CO 2 in the inspired air.

(fraction of baseline).
Valv(t ) = Alveolar Ventilation.
PiCO2 (t ) = Inspired pCO 2 at time ' t' (mmHg).
K p = Proportional gain.
K i = Integral gain.
K d = Derivative gain.
Simulation Case Study

Blayney et al. used a target controlled infusion pump to
find the optimal concentration of Propofol required for
exodontia in 300 adult patients.4 Their results indicate
2.1µg/ml to be the mean effect site concentration resulting
in sufficient sedation without respiratory depression.
Taking 2.1µg/ml as a target effect site concentration, I
devised 3 dosing regimens that could easily be
implemented with a simple infusion pump. Figure 1
shows that the first regimen reaches the effect site
concentration of 2.1µg/ml in 1.5 minutes with an initial
bolus, then maintains that conc. within 0.1µg/ml. The
second and third regimens reach 2.1µg/ml in 2.5 minutes
and 5 minutes respectively through infusions, then
maintain the effect site conc. within 0.1µg/ml.

The first term of this expression represents metabolic
production of CO2. Note that this model takes into
account the maximum 30% expected decrease in CO2
production at full drug effect. The second term represents
clearance of CO2 from the body by the lungs.
The above model was implemented as an iterative
simulator model in Matlab. See the description of the
model derivation in the appendix for other expressions
and parameters necessary to assemble this numeric model.
Inspired CO2 Controller

Equation 2 represents the proportional integral
derivative (PID) controller which was programmed into
Matlab to control the inspired CO2 based on minute
ventilation. This controller takes alveolar ventilation as an
input and uses baseline alveolar ventilation (6.5L/min in
my simulations) as the set point. The integral and
derivative gains are expressed as fractions of the partial
gain to facilitate manual tuning. PID gains were varied
until the system responded well for a step change in effect

FIGURE 1. Effect site concentration traces used as a case
study to tune and test the inspired CO2 PID controller. These
traces serve as the test input to the simulator.

Inspired Carbon Dioxide
The effect site traces in Figure 1 represent the range of
time that a sedationist may take to bring their patient to
the level of sedation necessary for exodontia.
The faster infusion is likely to cause more severe
respiratory depression than the slow infusion. These
effect site traces were fed into the computer simulator and
the non-steady state result in respiratory depression was
calculated. The PID gains were adjusted until the system
responded well to all three regimens.

RESULTS
Validation

To validate that my simulator function describes
Bouillon’s results, I manually entered the same effect site
concentration profiles as in his publication and ran my
model with inspired CO2 set to zero. Figure 2 gives the
results of my implementation of Bouillon's model. These
time values match those reported by Bouillon withing 2%
of the value at each point indicating that the computer
model is accurate.
Simulation Case Study

The PID gains that caused the PID controller to respond
with minimal overshoot to all three dosing regimens are
recorded in Table 1 along with other parameters of the
simulation.
Figure 3 gives the response of the controller and
respiratory model to the changes in effect site
concentration of Figure 1 both with and without inspired
CO2. The depth of the initial respiratory depression is
dependent on the rate of infusion with the faster infusion
causing the greatest depression as anticipated.

FIGURE 2. Results of my implementation of Bouillon’s
model, PaCO2 and alveolar ventilation resulting form a rapid
bolus and slow infusion of Propofol. Compare to Figure 5 in
Bouillon.5
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TABLE 1. PID gains and other simulation parameters.

P a ra m e te r

V a lu e

Kp =

300

Ki =

0 .0 0 5

Kd =

6 .5

V a lv ( 0 ) =

41 m m Hg

P e c C O 2 (0 ) =

41 m m Hg

Inspired CO2 prevents the initial drop in ventilation from
being as extreme as the control with the greatest
prevention observed for the slower infusion. The PID
controller is able to return the ventilation to its baseline
value in 4 to 7 minutes in contrast to the control which
doesn't return to baseline but equilibrates at about 68% of
normal ventilation. As expected, inspired CO2 had the
least significant effect on preventing the initial depression
for the bolus regimen, giving a mere 17% increase from
the minimum alveolar ventilation compared to the control.
Improvement is much more significant for the rapid and
slow infusion regimens, giving 72% and 89% increases
from the minimum alveolar ventilation without CO2
respectively. The equilibrium arterial CO2 was 48mmHg
for the control and 53mmHg with inspired CO2.
To reduce the initial drop in alveolar ventilation for the
bolus regimen, a second simulation was performed with
inspired CO2 administered for 2.5 minutes before the drug
is administered allowing more time to increase arterial
CO2. Target ventilation is set to 1.75x baseline for this
2.5 minute period. After drug administration the target
returns to baseline. Figure 4 compares ventilation with
and without the period of pre-inspired CO2. With the
period of pre-elevation of arterial CO2, ventilation quickly
elevates to twice it's resting value.

FIGURE 3. Alveolar ventilation depression due to a bolus,
rapid infusion and slow infusion of Propofol without inspired
carbon dioxide (dashed lines) and with inspired carbon
dioxide (solid lines).
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complicated by the wide variability of drug sensitivity
found in the population. A regimen that is safe for the
drug tolerant portion of the population may cause nearly
instant apnea in the drug sensitive population.14,1
Implications of Results

FIGURE 4. Alveolar ventilation depression due to a bolus
of Propofol without inspired carbon dioxide (dashed lines)
and with a period of inspired carbon dioxide both before and
after drug administration (solid lines).

Once the bolus is administered ventilation drops to 75%
of baseline then returns to baseline within 5 minutes.
This period of pre-elevation allows ventilation to remain
approximately 30% closer to normal when compared to
the case where inspired CO2 is given only after the bolus
is administered.

DISCUSSION
Respiratory Control

Respiratory drive, or desire to breath, is a function of
several factors including CO2 concentration in the
inspired air, CO2 concentrations in the venous and arterial
plasma, metabolic production of CO2, concentration of
CO2 in the respiratory center, drug concentrations
affecting respiratory drive and the apparent volume of
distribution of CO2 in the body.9,18
To predict how a subject will respond to changes in
inspired CO2, this complex system requires a numerical
model accounting for drug dynamics and CO2 kinetics
and dynamics. A computer based numerical model is
capable of simulating this system for a realistic sedation
protocol and can estimate the effect of inspired CO2 on
patients.
Such a model allows development and
adjustment of a system for administering inspired CO2 to
maintain respiration during conscious sedation without
endangering patients.
The need to insure patient safety from respiratory
depression during conscious sedation is augmented by the
recently increased use of fast acting and potent anesthetic
drugs such as Propofol. Propofol, while indicated only
for use by anesthesiologists, is finding more use by nonanesthesiologists in physicians offices and ambulatory
centers because of their rapid onset time and short half
life.15,16 Titrating sedation without causing apnea is

The simulation presented
above indicates that
respiratory depression may be reduced by feedback
controlled inspired CO2.
If the inspired CO2
administration begins when the drug is administered, the
initial drop is reduced but only slightly for a bolus or a
fast infusion. However, the steady-state respiratory
depression is eliminated within 7 minutes. Preventing the
steady state depression has little clinical value. The utility
of this technique comes in it's ability to protect drug
sensitive patients from becoming apneic. This equates to
the ability of the technique to prevent the initial
depression which is more severe than that of steady state.
To reduce this initial drop, I employed the technique of
administering CO2 before the drug administration. This
simulation was done for the bolus dose because the initial
drop is proportional to the rate of drug infusion. Inspired
CO2 administered after the bolus gives a 10% reduction in
the initial drop. Starting the CO2 controller 2.5 minutes
before the bolus gives a 40% reduction in the initial drop.
This is a substantial improvement. It means that a drug
sensitive patient would have to be about 30% more
sensitive to the drug to become apneic due to this bolus
while receiving inspired CO2 starting 2.5 minutes before
the drug administration.
One trade-off of pre-inspired CO2 is that it causes an
extra 2.5 minutes that the physician must wait before
starting. Another way to look at the technique is that
inspired CO2 allows the physician to give faster infusions
without increasing the risk of apnea. The 2.5 minute
period makes the technique less attractive from this
viewpoint. However, the ability to administer the drug
more quickly may make up for the extra 2.5 minutes
while increasing safety.
Limitations and Future Investigation

Reported model predictions are only as robust as the
models ability to emulate the real respiratory control
system. As the respiratory control system is much more
complex than the simple numerical model employed, its
predictions are limited. Bouillon selected a sigmoid
Emax model to determine the respiratory effect due to
Propofol, which asymptotically approaches full effect
(apnea) as drug concentration increases. This means that
the model will never show the respiration stopping
regardless of how high the drug concentration goes.
Bouillon expressed that the model responds well for the
concentration ranges they used (<3µg/ml) but it shouldn’t
be employed out of that range. In a study of 20
volunteers, Lee et al. found that 11 of the 20 subjects

Inspired Carbon Dioxide
became apneic below an effect site concentration of
4.0µg/ml.13 The Bouillon model predicts that a subject
will be breathing at 18% of baseline at this concentration.
This limitation prevented us from modeling a realistic
Propofol regimen that would cause apnea, to test with
inspired CO2.
In the clinic, patients vary greatly in drug sensitivity
causing a wide range in the extent of respiratory
depression caused by standard dosing regimens for
conscious sedation12,22,11. Some drug sensitive patients
become apneic or close to apneic after receiving dosing
regimens commonly employed and considered safe for a
particular procedure. This variability in response to
anesthetic drugs that I expect to see in the clinical setting
will allow us to observe the benefit of controlling inspired
CO2 for a spectrum of respiratory depression. I expect to
see that range of respiratory depressions reduced by the
inspired CO2. Volunteer studies need to be performed to
tune the PID controller on actual subjects. A mask and
computer controlled CO2 administration device must be
developed to do these studies. Finally, a production
prototype must be made and clinically tested before a
viable product can be made available.
In conclusion, this study has simulated the ability of
inspired CO2 to act as a respiratory stimulant during
conscious sedation.
The simulation indicated that
respiratory depression can be substantially reduced
according to the best available numerical model.
Volunteer and clinical studies should be done to develope
a clinically viable protective device for conscious
sedation.

The author thanks Dr. Dwayne Westenskow, Dr.
Joseph Orr and Dr. Thomas Bouillon for technical help
and review of the manuscript.

Using conservation of mass, Bouillon derives an
expression describing the change in arterial CO2 as a
function of alveolar ventilation5.
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where,
Ce (t ) = Effect site concentrat ion of propofol (µg/ml )
C 50 = Effect site concentrat ion of propofol
correspond ing to 50% effect ( µ g/ml)
PecCO 2 = Effect site partial pressure of
carbon dioxide (mmHg)

γ = Hill coefficien t
F = Gain factor for the slope of the non − linear
CO 2 response curve.

Equation four is substituted into equation three replacing
Valv(t). Since Propofol is known to decrease carbon
dioxide production by up to 30%, Bouillon introduces
another term to correct for metabolic production of CO2
using a negative sigmoid Emax model to vary CO2
production between baseline at zero drug effect, and 70%
baseline at full drug effect.
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where,
PaCO 2 (0 ) = Baseline arterial partial pressure of CO 2 (mmHg)
PaCO 2 (t ) = Arterial partial pressure of CO 2 at time ' t' (mmHg)
V&alv ( 0) = Baseline alveolar ventilatio n (L/min)
V& (t ) = Alveolar ventilatio n at time ' t' (L/min)
alv

V&alv (Ce , PecCO 2 ) =

The effect site concentration of carbon dioxide is
calculated as a single compartment first order transfer
from plasma to the effect site as follows:

APPENDIX

Vd CO 2 = Apparent volume of distributi on (L)

Bouillon then uses a sigmoid Emax model to describe the
ventilatory depressant effect of Propofol as a function of
Propofol effect site concentration and CO2 effect site
concentration.
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Vd CO 2
Vd CO 2
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where ke0,CO2 is the first order rate constant for diffusion
of CO2 in and out of the effect site. Bouillon determined
parameters for this model for 10 volunteers and reported
the values as a set of typical values with standard error.
Bouillon also reports a typical value for the CO2
elimination constant which is used in calculating VdCO2
as follows:
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V& (0)
Vd CO2 = alv
k elCO2

(7)

TABLE 2. Parameters used for the respiratory model.
Parameter

6

Typical Value

KeoCO2 , (1/min)

0.95

F ,(-)

4.37

Valv(0) , (L/min)

6.45

PaCO2(0) , (mmHg)

40.9

KelCO2 , (1/min)

0.11

C50 , (ug/ml)

1.33

gamma , (-)

1.68

where kelCO2 is the first order elimination constant of CO2
at baseline. Bouillon reports the model parameters as
recorded in table two.
Bouillon estimated PaCO2 from end-expiratory CO2 for
each subject. I communicated with Bouillon to insure that
the parameters that I used and my understanding of the
model were correct. For more specific details about this
model, see Bouillon’s publication sited above.
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